Thus, an anti-gH/gL mAb can block EBV infection of epithelial cells, an anti-gp42 mAb can block EBV infection of B cells (Li et al., 1995), and KSHV can be neutralized by sera raised against the whole virus (Dialyna et al., 2004), gH/gL (Naranatt et al., 2002), gB (Akula et al., 2001) or K8.1 (Sakamoto et al., 2010), but much of this neutralization has been weak (<threefold reduction in infection) in settings where infection may be suboptimal – for example, EBV infects epithelial cells poorly in vitro. This evidence concerns the gene KRT81 and infection.